Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection

Oncologist

Volumn 7, Issue 4, 2002, Pages 271-278

  Belhocine, Tarik ^a   Pierard, Gérald ^a   De Labrassinn, Michel ^a   Lahaye, Thierry ^a   Rigo, Pierre ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

18FDG PET; Cutaneous melanoma; Lymphatic mapping; Sentinel node

Indexed keywords

FLUORODEOXYGLUCOSE F 18; LYMPHOSCINT; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE; TUMOR VOLUME;

ADULT; AGED; DISEASE PROGRESSION; EXTREMITIES; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INJECTIONS, INTRAVENOUS; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECURRENCE; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036058601     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-4-271     Document Type: Article

References (41)

1. Cancer statistics, 1999
2. Regional nodal surgery for melanoma impacts recurrence rates and survival
3. The role of elective lymph node dissection in melanoma: Rationale, results, and controversies
4. The concept of sentinel node localization: How it started
5. The orderly progression of melanoma nodal metastases
6. Technical details of intraoperative lymphatic mapping for early stage melanoma
7. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial
8. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies
9. Lymphatic mapping and sentinel lymphadenectomy for melanoma: Past, present, and future
10. Sentinel lymph node biopsy for melanoma: Controversy despite widespread agreement
11. Oncological applications of FDG PET imaging
12. Oncological applications of FDG PET imaging: Brain tumors, colorectal cancer, lymphoma and melanoma
13. Positron emission tomography imaging in oncology
14. Sensitivity and specificity of positron emission tomography (PET) for the diagnosis of lymph node metastases
15. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2- deoxy-D-glucose in the imaging of malignant melanoma
16. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose
17. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose
18. Initial assessment of positron emission tomography for detection of non-palpable regional lymphatic metastases in melanoma
19. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
20. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy
21. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma
22. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma
23. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume
24. The use of lymphoscintigraphy and PET in the management of head and neck melanoma
25. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
26. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
27. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
28. Positron emission tomography scanning in malignant melanoma
29. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma
30. Capabilities of two- and three-dimensional FDG-PET for detecting small lesions and lymph nodes in the upper torso: A dynamic phantom study
31. PET image interpretation. Attenuation-corrected (ATN) vs non-attenuation corrected (NATN) images
32. 18F]FDG PET
33. Three-dimensional imaging characteristics of the HEAD PENN-PET scanner
34. Performance of a whole-body PET scanner using curve-plate NaI(TI) detectors
35. Recent developments in iterative image reconstruction for PET and SPECT
36. New developments in PET instrumentation: Quo vadis PET?
37. Comparison of 3-D reconstruction with 3D-OSEM and with FORE+OSEM for PET
38. Scatter modelling and correction strategies in fully 3-D PET
39. Energy-based scatter correction for 3-D PET scanners using NaI(T1) detectors
40. Molecular staging of malignant melanoma: Correlation with clinical outcome
41. Molecular analysis in evaluating the sentinel node in malignant melanoma